Department of Digestive Diseases and Clinical Nutrition, Tata Memorial Hospital, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400 012, India.
Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, 400 012, India.
Indian J Gastroenterol. 2023 Jun;42(3):396-403. doi: 10.1007/s12664-022-01337-1. Epub 2023 May 18.
Placement of biliary self-expanding metal stents (SEMS) has been effective for palliation of unresectable hilar malignant biliary obstruction. Optimal drainage in hilar obstruction may require placement of multiple stents. Data on multiple SEMS placement in hilar obstruction from India is sparse.
Retrospective review of patients with unresectable malignant hilar obstruction who underwent endoscopic bilateral SEMS insertion from 2017 to 2021 was done. Demographic details, technical success and functional success (decrease in the bilirubin value below 3 mg/dL at four weeks), immediate complications with 30-days mortality, requirement of re-intervention, stent patency and overall survival were studied.
Forty-three patients were included (mean age 54.9 years, 51.2% females). Thirty-six patients (83.7%) had carcinoma gallbladder as primary malignancy. Twenty-six patients (60.5%) were metastatic at presentation. Cholangitis was seen in 4/43 (9.3%). On cholangiogram, 26 (60.4%) had Bismuth type II block, 12 (27.8%) had type IIIA/B, 5 (11.6%) had type IV block. Technical success was achieved in 41/43 (95.3%) patients (38, side-by-side SEMS placement; 3, SEMS-within-SEMS in Y fashion). Functional success was achieved in 39 patients (95.1%). No moderate-severe complications were reported. Median post-procedure hospitalization was five days. Median stent patency was 137 days (interquartile range [IQR] 80-214 days). Re-intervention was required in four patients (9.3%) after mean 295.7 days. Median overall survival was 153 days (IQR 108-234 days).
Endoscopic bilateral SEMS in complex malignant hilar obstruction has good outcomes in the form of technical success, functional success and stent patency. Survival is dismal despite optimal biliary drainage.
放置胆道自膨式金属支架(SEMS)已被证明可有效缓解不可切除的肝门恶性胆道梗阻。在肝门梗阻中实现最佳引流可能需要放置多个支架。来自印度的关于肝门梗阻中多个 SEMS 放置的数据很少。
回顾性分析了 2017 年至 2021 年期间接受内镜双侧 SEMS 插入治疗的不可切除恶性肝门梗阻患者。研究了人口统计学细节、技术成功和功能成功(胆红素值在四周内降至 3mg/dL 以下)、30 天死亡率的即时并发症、再干预需求、支架通畅性和总生存率。
共纳入 43 例患者(平均年龄 54.9 岁,51.2%为女性)。36 例(83.7%)患者的原发性恶性肿瘤为胆囊癌。26 例(60.5%)患者在就诊时已发生转移。43 例患者中有 4 例(9.3%)发生胆管炎。胆管造影显示,26 例(60.4%)为 Bismuth Ⅱ型阻塞,12 例(27.8%)为ⅢA型/ⅢB 型,5 例(11.6%)为Ⅳ型阻塞。41/43 例(95.3%)患者(38 例,并排 SEMS 放置;3 例,SEMS 内 Y 型放置)获得技术成功。39 例(95.1%)患者获得功能成功。未报告中重度并发症。术后中位住院时间为 5 天。中位支架通畅时间为 137 天(四分位距 80-214 天)。295.7 天后,4 例患者(9.3%)需要再次干预。中位总生存时间为 153 天(四分位距 108-234 天)。
在复杂的恶性肝门梗阻中,内镜双侧 SEMS 的技术成功率、功能成功率和支架通畅率均较好。尽管进行了最佳的胆道引流,但生存情况仍不容乐观。